How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Want to cut your energy bills? Here’s how five experts are doing it 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
WALTHAM, Mass., March 14, 2016 -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Jonathan Lieber, Chief Financial Officer of Histogenics, will be presenting a corporate overview at the Alliance for Regenerative Medicine’s 4th Annual Cell & Gene Therapy Investor Day at the Metropolitan Club in New York, NY on Tuesday, March 22, 2016 at 4:50pm EDT.
A live-streaming webcast the Company’s presentation as well as all panels and company presentations will be available at: http://www.arminvestorday.com/webcast and will be published on the event’s website shortly after the conference.
About ARM’s Cell & Gene Therapy Investor Day
Organized by the Alliance for Regenerative Medicine (ARM) and co-hosted with Piper Jaffray, this one-day, high impact program provides institutional, strategic and venture investors with unique insight into the financing hypothesis for advanced therapies-based treatment and tools. The event includes clinical and commercial experts who are on-hand to address specific questions regarding the outlook for these products, as well as offer insight into how cell and gene therapies could impact the standard of care in key therapeutic areas such as cardiovascular disease, wound healing and tissue repair, ophthalmology, neurodegenerative diseases, diabetes and oncology. The program will include talks by key opinion leaders in the industry, life science investment experts and analysts covering the sector as well as presentations by more than 30 leading companies from across the globe.
About Histogenics Corporation
Histogenics is a leading regenerative medicine company developing and commercializing products in the musculoskeletal segment of the marketplace. Histogenics’ regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions to treat musculoskeletal-related conditions. Histogenics’ first investigational product candidate, NeoCart®, is currently in Phase 3 clinical development. NeoCart is an autologous cell therapy designed to treat cartilage defects in the knee using the patient’s own cells. Knee cartilage defects represent a significant opportunity in the United States, with an estimated 500,000 or more applicable procedures each year. NeoCart is designed to exhibit characteristics of articular, hyaline cartilage prior to and upon implantation into the knee and therefore does not rely on the body to make new cartilage, characteristics not exhibited in other current treatment options. For more information, please visit www.histogenics.com.
Contact: Investor Relations Tel: +1 (781) 547-7909 [email protected]
